29% (n = 24) had low Vit D at 12 months of whom 58% (n-14) were d

29% (n = 24) had low Vit D at 12 months of whom 58% (n-14) were deficient at baseline. Surprisingly, only 10/30 patients with initial deficient Vit D reported adherence with Vit D supplementation and 8/10 (80%) achieved Vit D sufficiency. In the remaining 20, Vit D remained deficient at follow up in 13 (65%) and had become sufficient in 7 without supplementation. The mean IBDQ scores did not change over the 12 months in either those who achieved sufficiency or remained deficient (became sufficient 48–50 cf remained deficient 48–49). In those who took AZD1208 the Vitamin D and became replete, only one had a significant increase in

IBDQ (>17 point increase). Of patients with Vit D sufficiency at baseline (n = 50), by 12 months 80%

(n = 40) remained Vit D sufficient while 20% (n = 10) had become Vit D deficient. Over the 12 months, neither patients who maintained sufficient vitamin D levels nor those who subsequently developed Vit D deficiency had any significant change in mean IBDQ Selleck Cisplatin score (remained sufficient: 52–54 cf became deficient: 52–48). By 12 months, of the 28 subjects with baseline abnormal BMD, 15 remained osteopenic/osteoporotic while 10/28 had normal BMD. Of those with normal baseline BMD, only 1/47 subsequently became osteopenic. Of note, in this patient, initial and follow-up Vit D measures were low (20 and 21 respectively). Conclusion: Vit D deficiency is highly prevalent, despite this being a predominantly ambulant outpatient sample. Impaired bone health, was also surprisingly common (>1/3 of the cohort), despite an average age of ∼32. Despite advice, Vit D therapy was poorly adopted, but biochemically successful when taken. As yet, the relationships amongst disease activity, QoL and Vit D and the role of supplementation are unclear, however, for prevention of future osteoporosis alone, it may be justified given the prevalence of deficiency we have discovered. 1. Mouli, VP and Ananthakrishnan, AN. Review article: vitamin D and inflammatory bowel diseases. Aliment Pharmacol Ther. 2014. Volume 39:2 pp 125–136. 2. Nowson CA, McGrath JJ, Ebeling PR, et al. 上海皓元 Vitamin

D and health in adults in Australia and New Zealand: a position statement. Med J Aust. 2012 Jun 18; 196(11): 686–687. PubMed PMID: 22708765. Epub 2012/06/20. eng. 3. Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, Tompkins C. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989; 96: 804–810. CHAMARA BASNAYAKE,1 GREGORY MOORE2 1Gastroenterology Registrar, Monash Health; 2Head of Inflammatory Bowel diseases Monash Health Introduction: Magnetic Resonance Enterography (MRE) is an increasingly used diagnostic imaging test in patients with either suspected or known IBD. We sought to determine the clinical utility of MRE in a tertiary referral center and compare it with other factors that influence diagnosis and management.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>